Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis

被引:7
|
作者
Wiegers, Hanke M. G. [1 ,2 ,8 ]
Schaafsma, Mirte [3 ,4 ]
Guman, Noori A. M. [1 ,2 ]
Zelisse, Hein S.
Mulder, Frits I. [1 ,2 ,5 ]
Middeldorp, Saskia [6 ]
van Es, Nick [1 ,2 ]
Mom, Constantijne H. [7 ]
机构
[1] Univ Amsterdam, Vasc Med, Amsterdam UMC, Amsterdam, Netherlands
[2] Amsterdam Cardiovasc Sci Pulm Hypertens & Thrombo, Amsterdam, Netherlands
[3] Netherlands Canc Inst, Ctr Gynaecol Oncol Amsterdam, Dept Gynaecol Oncol, Antoni Leeuwenhoek, Amsterdam, Netherlands
[4] Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands
[5] Tergooi Med Ctr, Dept Internal Med, Hilversum, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands
[7] Univ Amsterdam, Canc Ctr Amsterdam, Dept Gynaecol Oncol, Amsterdam UMC, Amsterdam, Netherlands
[8] Univ Amsterdam, Dept Vasc Med, Amsterdam UMC, Amsterdam Cardiovasc Sci, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
关键词
haemostasis; neoplasms; thrombosis; venous thromboembolism; women; PROPHYLAXIS; PREVENTION; ANTICOAGULANTS;
D O I
10.1016/j.jtha.2022.11.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Venous thromboembolism (VTE) is a frequent complication in patients with ovarian cancer after major surgery. Based on limited data, international guidelines recommend extended thromboprophylaxis for up to 28 days. Objectives: To assess the incidence of VTE and bleeding within 30 days following major surgery in patients with ovarian cancer and to evaluate the association between VTE and thromboprophylaxis duration. Methods: This was a single-center, retrospective, "before-after" cohort study in patients with ovarian cancer undergoing major surgery. Before July 2019, the local protocol mandated a standard course of thromboprophylaxis during hospital stay only. From July 2019 onward, patients received extended thromboprophylaxis for 28 days. The cumulative incidences of VTE and major bleeding within 30 days after surgery were estimated using the Kaplan-Meier method, with 95% confidence intervals (CIs). Cox regression analysis was performed to evaluate the association between thromboprophylaxis duration and VTE incidence. Results: Between January 2018 and December 2020, 250 women were included, of which 118 (47.2%) received extended and 132 (52.8%) standard thromboprophylaxis. During follow-up, 12 patients developed VTE (cumulative incidence, 4.8%; 95% CI, 2.1-7.4) and 2 major bleeding (cumulative incidence 0.8%; 95% CI, 0.0-1.9). Compared with standard thromboprophylaxis, VTE incidence was numerically lower with extended duration of thromboprophylaxis (5/118 [4.2%] vs 7/132 [5.3%]) but not significantly different (hazard ratio, 0.80; 95% CI, 0.25-2.52). The risk of major bleeding was similar in both groups (1/118 [0.8%] vs 1/132 [0.8%]; hazard ratio, 1.12; 95% CI, 0.07-17.89). Conclusions: The cumulative VTE incidence in patients with ovarian cancer following major surgery was considerable. Extended thromboprophylaxis was safe and associated with a numerically lower risk of VTE but not significantly different.
引用
收藏
页码:294 / 302
页数:9
相关论文
共 50 条
  • [21] Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
    Chi, G.
    Goldhaber, S. Z.
    Kittelson, J. M.
    Turpie, A. G. G.
    Hernandez, A. F.
    Hull, R. D.
    Gold, A.
    Curnutte, J. T.
    Cohen, A. T.
    Harrington, R. A.
    Gibson, C. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (10) : 1913 - 1922
  • [22] Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis
    Bergqvist, David
    JOURNAL OF SURGICAL ONCOLOGY, 2007, 95 (02) : 167 - 174
  • [23] The risk of venous thromboembolism after open radical prostatectomy and the role of extended thromboprophylaxis
    Cetti, R.
    Vijayan, S.
    Appu, S.
    BJU INTERNATIONAL, 2014, 113 : 111 - 111
  • [24] The impact of extended thromboprophylaxis on the risk of venous thromboembolism after open radical prostatectomy
    Wang, L.
    Harper, M.
    Cetti, R.
    BJU INTERNATIONAL, 2016, 117 : 110 - 111
  • [25] High Incidence of In-Hospital Venous Thromboembolism Early After Lung Transplantation Despite Thromboprophylaxis
    Ruigrok, D.
    Admiraal, J.
    Boersma, L.
    Schonwetter, R.
    Post, M. C.
    Luijk, B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S475 - S475
  • [26] Beyond prophylaxis: extended risk of venous thromboembolism in ovarian cancer
    Bourne, Beth E.
    Langstraat, Carrie
    McGree, Michaela E.
    Amy, Weaver
    Sarangi, Shikha
    Mokri, Bahareh
    Heit, John A.
    Mariani, Andrea
    Cliby, William A.
    Bakkum, Jamie
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 219 (04) : E25 - E25
  • [27] Missed Venous Thromboembolism after Major Cancer Surgery
    Rattan, Rishi
    Parreco, Joshua
    Eidelson, Sarah A.
    Gold, Joann
    Vasileiou, Georgia
    Zakrison, Tanya L.
    Yeh, Daniel D.
    Namias, Nicholas
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 227 (04) : E58 - E58
  • [28] Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
    de Oliveira, Andre Luiz Malavasi Longo
    Pereira, Renata Fernanda de Oliveira
    Agati, Leandro Barile
    Ribeiro, Camilla Moreira
    Suguiura, Gabrielly Yukimi Kawamura
    Cioni, Claudia Helena
    Bermudez, Marilsa
    Pirani, Marcia Bermudez
    Caffaro, Roberto Augusto
    Castelli, Valter
    Aguiar, Valeria Cristina Resende
    Volpiani, Giuliano Giova
    Paschoa, Adilson
    Macedo, Ariane Vieira Scarlatelli
    Silva, Pedro Gabriel Melo
    Guerra, Joao Carlos de Campos
    Fareed, Jawed
    Lopes, Renato Delascio
    Ramacciotti, Eduardo
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [29] Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
    de Oliveira, Andre Luiz Malavasi Longo
    Pereira, Renata Fernanda de Oliveira
    Agati, Leandro Barile
    Ribeiro, Camilla Moreira
    Suguiura, Gabrielly Yukimi Kawamura
    Cioni, Claudia Helena
    Bermudez, Marilsa
    Pirani, Marcia Bermudez
    Caffaro, Roberto Augusto
    Castelli Jr, Valter
    Aguiar, Valeria Cristina Resende
    Volpiani, Giuliano Giova
    Paschoa, Adilson
    Macedo, Ariane Vieira Scarlatelli
    Silva, Pedro Gabriel Melo de Barros e
    Guerra, Joao Carlos de Campos
    Fareed, Jawed
    Lopes, Renato Delascio
    Ramacciotti, Eduardo
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [30] Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
    de Oliveira, Andre Luiz Malavasi Longo
    de Oliveira Pereira, Renata Fernanda
    Agati, Leandro Barile
    Ribeiro, Camilla Moreira
    Kawamura Suguiura, Gabrielly Yukimi
    Cioni, Claudia Helena
    Bermudez, Marilsa
    Pirani, Marcia Bermudez
    Caffaro, Roberto Augusto
    Castelli, Valter
    Resende Aguiar, Valeria Cristina
    Volpiani, Giuliano Giova
    Paschoa, Adilson
    Scarlatelli Macedo, Ariane Vieira
    Silva, Pedro Gabriel Melo
    de Campos Guerra, Joao Carlos
    Fareed, Jawed
    Lopes, Renato Delascio
    Ramacciotti, Eduardo
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28